"As the only FDA-approved GLP-1 therapy in a pill, now recognised for its proven cardiovascular benefits, a new benchmark has been set for future oral innovations," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk
(As we all know, pharmaceutical patents are a tricky business, and Novo Nordisk likely followed the traditional pharma playbook of patenting the drug for different uses over time, which would explain the repeated introduction of new brand names and claims.) Nonetheless, several major generic drug companies are waiting in the wings to challenge Novo Nordisk with generic versions of Liraglutide once the patent runs out, including pharma giant Novartis generic subsidiary Sandoz, Teva Pharmaceutical, and Viatris (formerly Mylan)
The complaint alleges that Novo Nordisk was negligent in allowing Ozempic to be sold, failed to warn, negligently designed Ozempic and other semaglutide drugs, negligently marketed the drug, and violated Pennsylvania unfair trade practices
Pulling this off in house speaks volumes about our regional biotech capabilities
